Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Short Term Debt

Last Annual Value

3.83M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Short Term Debt

NAUT · NASDAQ
CompanyShort Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.83M
N/AN/AN/A 
3.02M
N/A8.7%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
0.00
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
2.43M
N/AN/AN/A
4.21M
N/A-28.5%41.3%
78.00K
N/AN/AN/A
397.10K
N/AN/AN/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
155.11M
920.4%192.2%100.7%
443.00K
-6.6%N/AN/A
112.06K
N/AN/AN/A
199.04K
N/A-20.9%N/A
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58